This handout is for type 2 diabetes (chronic outpatient). Your care team identified this based on: hba1c ≥6.5% / elevated fpg / 2-h ogtt ≥200 (ada 2026 §2 diagnostic criteria).
Other reasons your team may use this plan: polyuria + polydipsia + weight loss per ada 2026 §2; established t2dm (titration / annual review per ada 2026 §4); prediabetes for surveillance + dpp referral per ada 2026 §3.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| metformin | 500 mg | PO | BID with meals; titrate to 1000 mg BID over 4 wk | ADA 2026 §9 foundation; A1c approx -1.0 to -1.5%, glycemic effect 1-2 wk. UKPDS 80 legacy: metformin MI -33% (p=0.005), all-cause death -27% (p=0.002) at 10 y post-trial (PMID 18784090). B12 q1-2y after 4 y. |
Plan: ADA 2026 §9 — comorbidity-first glycemic stepwise ladder (cardiorenal indications independent of A1c)
Use these zones to know what to do based on how you feel.
Call 911 or go to the nearest emergency room right away if you have:
DSME, vaccinations (flu/pneumococcal/COVID/RSV/Tdap/HepB/zoster), psychosocial + fear-of-hypoglycemia + anxiety screen (ADA 2026), pre-pregnancy counseling
Guideline: ADA Standards of Care 2026 + AACE 2023 + KDIGO 2024 Diabetes-CKD + EASD/ADA 2022 Hyperglycemia Consensus + 2026 ACC/AHA Lipid + 2025 AHA/ACC HTN + AASLD 2023 MASH (resmetirom 2024 FDA approval)